1Beta-Blocker Evaluation of Survival Trial Investigators.A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure[].The New England Journal of Medicine.2001
2Cohn JN,Tognoni G.A randomised trial of the angiotensin-receptor blocker valsartan in chronic heart failure[].The New England Journal of Medicine.2001
3Feldman RD.Adrenergic receptor polymorphisms and cardiac function(and dysfunction): a failure to communicate[].Circulation.2001
4Hunt SA,Baker DW,Chin MH,et al.ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult:executive summary.A report of the ACC/AHA task force on practice guidelines[].Journal of the American College of Cardiology.2001
5MERIT-HF Study Group.Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Trial in Congestive Heart Failure(MERIT-HF)[].The Lancet.1999
6Exner DV,Dries DL,Domanski MJ.Lesser response to angiotensinconverting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction[].The New England Journal of Medicine.2001
7Swedberg K,Bristow MR,Cohn JN,et al.Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure[].Circulation.2002
8Packer M,Coats AJ,Fowler MB,et al.Effects of carvedilol on survival in severe chronic heart failure[].The New England Journal of Medicine.2001
9Wikstrand J,Hjalmarson A,Waagstein F,et al.Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure Analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF)[].Journal of the American College of Cardiology.2002
